Tardive dyskinesia and atypical antipsychotic drugs

@article{Casey1999TardiveDA,
  title={Tardive dyskinesia and atypical antipsychotic drugs},
  author={Daniel E. Casey},
  journal={Schizophrenia Research},
  year={1999},
  volume={35},
  pages={S61-S66}
}
  • D. Casey
  • Published 1999
  • Medicine, Psychology
  • Schizophrenia Research
Typical antipsychotic agents produce central nervous system effects, especially extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Nearly every patient who receives neuroleptic therapy has one or more identifiable risk factors for TD, among the most significant of which are older age, female gender, presence of EPS, diabetes mellitus, affective disorders, and certain parameters of neuroleptic exposure (i.e. dose and duration of therapy). The typical course of TD is a gradual onset after… Expand
Tardive dyskinesia in elderly patients: an update.
  • R. Goldberg
  • Medicine
  • Journal of the American Medical Directors Association
  • 2003
TLDR
The relationship between TD and aging and its treatment in elderly patients is reviewed, with a focus on older age. Expand
Extrapyramidal Symptoms with Atypical Antipsychotics
TLDR
The use of atypical antipsychotics as first line therapy for the treatment of schizophrenia is based largely on their reduced risk of EPS compared with conventional antipsychotic medications, Nevertheless, EPS with these drugs can occur, particularly when prescribed at high doses. Expand
Untitled Page
Development of extrapyramidal symptoms (EPS), particularly tardive dyskinesia (TD), has long been a troubling side effect for patients taking antipsychotics. Atypical antipsychotics have been hailedExpand
Tardive Dyskinesia: Treatment with Aripiprazole
  • N. Kang, Moon-Doo Kim
  • Medicine
  • Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2011
TLDR
Aripiprazole has a unique mechanism of action and has various effects in tardive dyskinesia, and the drug acts as a partial D2 receptor agonist that can stabilize D2 up-regulation and a 5-HT2A receptor antagonist that can increase the release of dopamine in the striatum. Expand
Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms
TLDR
The reported results of the CATIE trial regarding EPS are explored and the differentiation of the atypicals from perphenazine on EPS is emphasized and how these results should be incorporated into daily practice for the clinician is emphasized. Expand
Historical perspectives on tardive dyskinesia
Tardive dyskinesia (TD) is a persistent hyperkinetic movement disorder associated with dopamine receptor blocking agents including antipsychotic medications. Although uncertainty and concern aboutExpand
Tardive dyskinesia and intellectual disability: an examination of demographics and topography in adults with dual diagnosis and atypical antipsychotic use.
TLDR
The current study seeks to expand the literature related to Tardive Dyskinesia and atypical antipsychotic medication utilizing a measure of medication side effects, the Matson Evaluation of Drug Side Effects (MEDS). Expand
Tardive dyskinesias and antipsychotics: a review
TLDR
These new atypical antipsychotic actions are doubtlessly promising, but they cannot ignore the notion of risk–benefit; regular monitoring and listening to the subjective experience of the patients must remain uppermost in the choice of therapy. Expand
Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia.
TLDR
Data from six trials showed that there may be a clinically important improvement in TD symptoms after GABA agonist treatment compared with placebo at six to eight weeks follow-up, and the risk of bias in the included studies was unclear. Expand
Investigating a novel antioxidant approach to the treatment of tardive dyskinesia
TLDR
The purpose of the current study was to establish a valid animal model of TD, followed by the evaluation of the behavioural and neurochemical effects of chronic NAC administration at various doses in a nonpathological state, i.e. in healthy rats. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Treatment of tardive dyskinesia.
TLDR
Although the new generation of atypical antipsychotic agents could some day eliminate concerns about tardive dyskinesia, this disorder remains a significant clinical problem for patients and physicians and efforts to understand the neurobiology of TD may shed light on this persistent clinical conundrum. Expand
Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia.
TLDR
The pressing need is for novel compounds which treat schizophrenia and are free of the undesirable motor system effects (a nonneuroleptic neuroleptic). Expand
Tardive dyskinesia and diabetes mellitus.
TLDR
Possible pathophysiologic mechanisms for the increased prevalence of tardive dyskinesia in neuroleptic-treated patients with diabetes will be discussed. Expand
Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia?
  • D. Casey
  • Psychology, Medicine
  • International clinical psychopharmacology
  • 1997
TLDR
The advent of new agents such as sertindole, olanzapine and seroquel seems likely to fulfill the promise that it is possible to have antipsychotic agents with a low EPS liability, and possibly a low risk of tardive dyskinesia. Expand
Tardive dyskinesia in the aged. Duration of treatment relationships.
TLDR
These analyses showed the greatest rise in risk of TD occurred within the first two years of drug therapy, and logistic multiple regression analysis verified these relationships and was more successful at predicting TD. Expand
Tardive dyskinesia in older out‐patients: a follow‐up study
TLDR
Although TD was common, it rarely progressed in this naturalistic setting, suggesting that even for older patients maintenance neuroleptic treatment may be feasible for chronic psychosis. Expand
The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.
TLDR
Neuroleptic-treated diabetics had a significantly higher prevalence and severity of tardive dyskinesia, and it is suggested that diabetes mellitus should be examined further as a risk factor for tardiv dysKinesia. Expand
The differential diagnosis of tardive dyskinesia
  • D. Casey
  • Psychology, Medicine
  • Acta psychiatrica Scandinavica. Supplementum
  • 1981
TLDR
A thorough history, including past and present drug use, and a complete physical, neurological, and psychiatric examination, accompanied by appropriate laboratory tests, are often necessary to make the correct differential diagnosis of dyskinesias. Expand
Prospective study of tardive dyskinesia incidence in the elderly.
TLDR
Investigation of the incidence of tardive dyskinesia in elderly individuals beginning treatment with antipsychotic drugs found psychiatric (as opposed to organic) diagnosis and presence of extrapyramidal signs early in treatment were associated with increased tardiv dyskine vulnerability. Expand
Tardive dyskinesia: a 3-year follow-up study.
TLDR
The amount of purposeless trunk and limb movement present proved to be a relatively stable phenomenon, showing only a slight increase with age and no change over the follow-up period. Expand
...
1
2
3
4
...